HeartSciences Business Summary

HeartSciences Inc. (HSCS) is an AI-powered medical technology firm specializing in the transformation of traditional electrocardiography (ECG) into a high-precision diagnostic tool for early heart disease detection. The company operates through a dual-revenue model: a SaaS-based "pay-per-test" structure for its MyoVista Insights™ cloud platform and hardware sales of its proprietary MyoVista® wavECG™ device. Business segments are divided into its hardware-agnostic healthcare IT platform, which serves as a marketplace for third-party AI-ECG algorithms, and its proprietary diagnostic hardware and AI-software suite targeting impaired cardiac relaxation. Direct competitors include GE HealthCare Technologies, Nihon Kohden, AliveCor, and HeartBeam; HeartSciences differentiates itself by focusing on "frontline" clinical settings, providing low-cost, imaging-grade diagnostic insights using continuous wavelet transform (CWT) signal processing. The leadership team is led by Chairman and CEO Andrew Simpson, who brings over 30 years of experience, including his tenure as Group CEO of the $8 billion Peel Group. He is supported by COO Mark Hilz, a veteran entrepreneur who previously grew the NASDAQ-listed INX to $400 million in revenue, and CFO Danielle Watson, formerly a senior leader at Moss Adams with extensive SEC reporting expertise. The technical division is headed by VP of R&D Aaron Peterson, whose background includes senior engineering roles at St. Jude Medical and Boston Scientific. Notable institutional backing includes the Icahn School of Medicine at Mount Sinai, which is a significant shareholder and development partner, while the board features seasoned directors such as Bruce Bent and David R. Wells.